Related Experiment Video

Updated: Jun 28, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

[New approaches in antibiotic therapies in chronic pulmonary diseases]

Umit Celik1, Emine Kocabas

  • 1Division of Children Infectious Diseases, Department of Children's Health and Diseases, Faculty of Medicine, Cukurova University, Adana, Turkey.

Tuberkuloz Ve Toraks
|October 22, 2008
PubMed

Insights

This review examines antibiotic use for chronic lung diseases like cystic fibrosis and bronchiectasis in children and adults. Effective antibiotic regimens are crucial for managing infections and improving patient outcomes.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Pharmacology

Context:

  • Chronic lung diseases pose significant challenges in both pediatric and adult populations.
  • Advances in diagnostics, vaccinations, and antibiotic therapies have improved patient longevity.
  • Concomitant infections critically impact the prognosis of these conditions.

Purpose:

  • To review current antibiotic usage regimens for common chronic pediatric lung diseases.
  • To discuss management strategies for cystic fibrosis, bronchiectasis, and allergic bronchopulmonary aspergillosis.
  • To highlight the importance of appropriate antibiotic selection in optimizing patient outcomes.

Summary:

  • This review focuses on antibiotic treatment strategies for cystic fibrosis, bronchiectasis, and allergic bronchopulmonary aspergillosis.
  • It evaluates the efficacy and rationale behind various antibiotic regimens.
  • The discussion emphasizes the role of antibiotics in managing infections associated with these chronic respiratory conditions.

Impact:

  • Provides guidance on optimizing antibiotic therapy for chronic lung diseases.
  • Aims to improve clinical decision-making in managing pediatric and adult respiratory infections.
  • Contributes to better patient outcomes and quality of life for individuals with chronic lung conditions.

More Related Videos

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...